
LQDA Stock Forecast & Price Target
LQDA Analyst Ratings
Bulls say
Liquidia is demonstrating strong growth momentum, with sales annualizing at around $682 million and a significant market share increase of 30% in the 2nd quarter of 2026. The company's financials show increasing profitability and positive cash flow, with cash reserves of $284.2 million as of the end of 2nd quarter of 2026. Looking ahead, the company's strategic expansion of its development pipeline and sales force, as well as its focus on inhaled dry powder delivery technology, positions it well for continued success in the treatment of pulmonary hypertension.
Bears say
Liquidia is positioned to capitalize on the growing market for pulmonary hypertension treatment with its lead candidate Yutrepia, but faces potential legal risks with ongoing patent lawsuits and competition from novel therapies. However, the company has shown strong growth in key metrics and a strong pipeline, though its dependence on a single product could pose a risk to future financial performance. Monitoring legal developments and market adoption will be key for evaluating the company's future prospects.
This aggregate rating is based on analysts' research of Liquidia Technologies Inc and is not a guaranteed prediction by Public.com or investment advice.
LQDA Analyst Forecast & Price Prediction
Start investing in LQDA
Order type
Buy in
Order amount
Est. shares
0 shares